It was reported that CD79a-mediated Lyn-dependent activation of PI3K/AKT/mTOR signaling also occurs in bortezomib (an FDA-approved 26S proteasome inhibitor) resistant MCL [160]. Here, CD79A is linked to mantle cell lymphoma.